At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
losartan potassium +4 moredrug
Likely dose
losartan potassium 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, 5-Period Crossover Study to Evaluate the Effects of a Single Dose of Losartan, a Single Dose of Isosorbide Mononitrate (ISMN), and Single Doses of Losartan + ISMN on Central Blood Pressure Measurements in Mildly Hypertensive Patients
In Brief
A Phase 1 clinical trial evaluating losartan potassium, Comparator: isosorbide mononitrate (ISMN), and 2 other interventions for Hypertension. Completed, enrolled 13 participants.
Detailed Summary
This study will qualify a functional model that can measure central blood pressure and vascular compliance effects through noninvasive means.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
Primary CompletionDec 2006
First PostedJul 2009
TodayJul 2026
First PostedJul 22, 2009
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2006
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.9 years ago
Interventions
losartan potassiumdrug
Single dose losartan 100 mg in one of five treatment periods
Comparator: isosorbide mononitrate (ISMN)drug
Single dose ISMN 60 mg in one of five treatment periods
Comparator: losartan + ISMNdrug
Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
Comparator: losartan + ISMNdrug
Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
Comparator: Placebodrug
Single dose placebo only in one of five treatment periods